Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

Molecular Cancer Therapeutics

Volumn 4, Issue 1, 2005, Pages 125-139

  Nutley, Bernard P ^a   Raynaud, Florence I ^a   Wilson, Stuart C ^a   Fischer, Peter M ^b   Hayes, Angela ^a   Goddard, Phyllis M ^a   McClue, Steven J ^b   Jarman, Michael ^a   Lane, David P ^b   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DEUTERIUM; DRUG METABOLITE; ROSCOVITINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYCLIN-DEPENDENT KINASES; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; PURINES; TISSUE DISTRIBUTION;

EID: 14044274202     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
2. Garrett MD, Fattaey A. CDK inhibition and cancer therapy. Curr Opin Genet Dev 1999;9:104-11.
3. Brooks G, La Thangue N. The cell cycle and drug discovery: the promise and the hope. Drug Design Today 1999;4:455-64.
4. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000;43:1-18.
5. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86.
6. Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett 1998;8:793-8.
7. Legraverend M, Ludwig O, Bisagni E, et al. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin D-dependent kinase inhibitors. Bioorg Mad Chem Lett 1999;7:1281-93.
8. Havlicek L, Hanus J, Vesely J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997;40:408-12.
9. Wang S, McClue SJ, Ferguson JR, et al. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry 2001;12:2891-4.
10. Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
11. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine CDK2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004;3:353-62.
12. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
13. Fischer PM, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2003;12:955-70.
14. De la Motte S, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Intl J Clin Pharmacol Ther 2004;42:232-9.
15. Gray NS, Kwon S, Schultz PG. Combinatorial synthesis of 2,9-disubstituted purines. Tetrahedron Lett 1997;38:1161-4.
16. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
17. Busch KL, Glish GL, McLuckey SA. Mass spectrometry/mass spectrometry: techniques and applications of tandem mass spectrometry. New York (NY): VCH Publishers; 1988.
18. Morrison RT, Boyd RN. Organic chemistry. 5th ed. Boston (MA): Allyn and Bacon, Inc.: 1987; p. 1370.
19. Netter KJ. Inhibition of oxidative drug metabolism in microsomes. Pharmacol Ther 1980;10:515-35.
20. Jakoby W, Bend JR, Caldwell J. Metabolic basis of detoxication: metabolism of functional groups. New York (NY): Academic Press; 1982.
21. Chmela Z, Vesely J, Lemr K, et al. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route. Drug Metab Dispos 2001;29:326-34.
22. Rypka M, Vesely J, Chmela Z, et al. In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes. Xenobiotica 2002;32:1017-103.
23. Testa B, Jenner P. Drug metabolism: chemical and biochemical aspects. New York (NY): Marcel Dekker; 1976.
24. Roy SK, Gupta E, Dolan ME. Pharmacokinetics of O 6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos 1995;23:1394-9.
25. 6 -benzylguanine. Biochem Pharmacol 1995;50:1385-9.
26. 6-benzylguanine, an inactivator of O 6-alkylguanine-DNA alkyltransferase. Cancer Res 1994;54:5123-30.
27. 6-benzylguanine in the nonhuman primate. Clin Cancer Res 1998;4:2891-4.
28. 6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 1998; 16:1803-10.
29. Farmer PB, Foster AB, Jarman M, Oddy MR, Reed DJ. Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. J Med Chem 1978;21:514-20.
30. Cervenkova K, Belejova M, Chmela Z, et al. In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes. Physiol Res 2003;52:467-74.